The research team, led by investigators at Mazandaran University of Medical Sciences in Iran along with collaborators at several other Iranian institutions, conducted the review in accordance with PRISMA guidelines, the international standard for reporting systematic reviews. They searched Embase, PubMed, and Scopus for studies published up to 2025, with two reviewers independently selecting studies, extracting data, and assessing report quality using the STROBE checklist, a tool designed to evaluate the rigor of observational research. Because the included studies differed substantially in design, populations, and outcome measures, the authors chose a narrative synthesis rather than a statistical meta-analysis, a decision that reflects the messy reality of real-world evidence but also limits the precision of any single pooled estimate.

To understand why this matters, it helps to know what the QTc interval actually represents. Every heartbeat is triggered by an electrical impulse that sweeps through the ventricles, the heart’s main pumping chambers, causing them to contract and push blood to the body. After contraction, the cardiac cells must electrically reset before the next beat can occur, and the duration of that reset is measured on the electrocardiogram as the QT interval. Because the raw QT shortens as heart rate increases, clinicians apply a correction formula, producing the QTc value. When QTc is prolonged, the heart’s electrical recovery is delayed, creating a window in which stray electrical signals can trigger a distinctive and dangerous rhythm called torsades de pointes, a form of polymorphic ventricular tachycardia that can degenerate into sudden cardiac arrest.

Methadone interferes with this reset process by blocking hERG potassium channels, the molecular pores in cardiac cell membranes that allow potassium ions to flow outward during the repolarization phase. This is the same mechanism implicated in a long list of drugs that have been withdrawn or black-boxed over the past decades, from certain antihistamines to some antipsychotics. Methadone’s blockade is dose-dependent, meaning higher concentrations of the drug in the blood translate into greater channel inhibition and longer QTc intervals. The synthetic opioid’s long and variable half-life, along with wide differences between individuals in how their livers metabolize it through the CYP enzyme system, means that blood levels can vary dramatically between patients taking what appears to be the same dose.

The review’s synthesis of the 25 included studies points to several consistent patterns. First, the association between methadone and QTc prolongation appears dose-related, with patients on higher doses showing greater electrical changes. Second, the effect is more pronounced in female patients, a sex difference that echoes broader cardiac electrophysiology, since women inherently have longer baseline QTc intervals and appear more susceptible to drug-induced repolarization delays, particularly during hormonal fluctuations. Third, and perhaps most actionable for practicing clinicians, concomitant medications amplify the risk, with benzodiazepines standing out as a particularly concerning co-prescription. Many patients in methadone maintenance programs also receive benzodiazepines for anxiety, insomnia, or co-occurring psychiatric conditions, often without either prescriber fully appreciating the cumulative cardiac burden.

Notably, the review reports that several studies documented QTc prolongation even at relatively low methadone doses. This finding challenges a common clinical assumption that only patients on high-dose methadone, typically defined as exceeding 100 milligrams per day in many guidelines, require cardiac scrutiny. If electrical changes can emerge at modest doses, then dose thresholds alone are an unreliable safeguard, and individual vulnerability factors, including genetic variations in potassium channel genes, electrolyte disturbances such as low potassium or magnesium, structural heart disease, and liver impairment, become critical pieces of the risk puzzle. Patients with any of these features may be pushed across the arrhythmia threshold by exposures that would be tolerated by healthier hearts.

The clinical implications are substantial because methadone occupies a unique and indispensable position in addiction medicine. As a full opioid agonist with a long duration of action, it stabilizes patients, suppresses withdrawal and cravings, and is associated with reduced illicit opioid use, reduced overdose mortality, and improved retention in treatment. Buprenorphine, a partial agonist, offers an alternative with a comparatively more favorable cardiac profile, but it does not suit every patient, and switching therapies carries its own risks of relapse and dropout. The review’s authors therefore do not call for restricting access to methadone; instead, they underscore the importance of careful cardiac monitoring and individualized risk assessment, positioning the findings as a call for smarter prescribing rather than frightened abstinence from an effective therapy.

What would smarter prescribing look like in practice? The evidence assembled in this review supports a layered approach. Before initiating methadone, clinicians can obtain a baseline electrocardiogram and review the patient’s medication list for other QT-prolonging agents, including certain antidepressants, antipsychotics, macrolide antibiotics, and antiarrhythmic drugs. Serum potassium and magnesium levels can be checked and corrected where needed. Follow-up electrocardiograms become especially important after dose increases, after adding interacting medications, and in patients with liver disease, since impaired metabolism can raise methadone blood concentrations unpredictably. Patients should be educated about warning symptoms, including fainting episodes, palpitations, and seizures, which may represent arrhythmic events rather than benign phenomena. When benzodiazepine co-prescription is unavoidable, the combination warrants heightened surveillance and honest conversations about the added risk.

The review also highlights structural gaps in how methadone programs operate. Many opioid treatment clinics, particularly in low-resource settings, lack routine access to electrocardiography, and screening practices vary widely between and within countries. The authors of the review received no external funding and declared no competing interests, and their synthesis draws exclusively on previously published literature, which means the quality of the underlying studies shapes the strength of the conclusions. Observational studies are vulnerable to confounding, since patients on high-dose methadone often differ from those on low doses in ways that independently affect cardiac health, including duration of opioid use, co-occurring diseases, and lifestyle factors. The narrative format of the synthesis, while appropriate given the heterogeneity, means the review cannot quantify a single pooled risk estimate, and the authors are careful not to overstate what the data support.

Nevertheless, the consistency of the signal across 25 independent studies is difficult to dismiss, and the biological mechanism is well understood. For the millions of people currently in methadone maintenance therapy worldwide, the message is not panic but partnership: patients deserve to know that their medication carries a measurable cardiac risk that is manageable with proper monitoring, and clinicians deserve clear, evidence-based protocols for identifying who is most vulnerable. As opioid use disorder continues to drive devastating mortality globally, the challenge for the field is to preserve the life-saving benefits of methadone while closing the surveillance gaps that allow a treatable electrical abnormality to progress unnoticed toward a preventable tragedy. This review provides the evidence base for that conversation, and it arrives at a moment when the addiction treatment community is actively rethinking how safety monitoring should be built into every prescription.

Subject of Research: QTc prolongation and cardiac arrhythmia risk associated with methadone maintenance therapy

Article Title: Risk factors and clinical implications of QTc prolongation in methadone maintenance therapy: a systematic review

Article References: Alaedini Shoormasti, K., Behroozi, Z., Souresrafil, A., Salimi, M., Sefidgarnia Amiri, M., Zarghami, M., & Tashakori-Miyanroudi, M. (2026). Risk factors and clinical implications of QTc prolongation in methadone maintenance therapy: a systematic review. BMC Pharmacology and Toxicology. https://doi.org/10.1186/s40360-026-01251-8

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01251-8

Keywords: methadone, QTc prolongation, opioid substitution therapy, ventricular arrhythmia, torsades de pointes, drug safety, cardiac monitoring, benzodiazepines, systematic review, hERG potassium channels, pharmacology, addiction medicine

The design of the study is deliberately straightforward. Half of the participants, all of whom will have alcohol use disorder, opioid use disorder, or both, will be randomly assigned to receive once-weekly semaglutide injections for 52 weeks. Crucially, the medication will be offered as an additional support layered on top of existing care, not as a replacement for traditional addiction treatment. Participants will remain eligible for all other behavioral health supports throughout the study period. Recruitment will focus on individuals who are clinically appropriate for GLP-1 medications and who face an elevated risk of criminal-justice involvement, a targeting strategy that reflects the county’s interest in directing new interventions toward those with the greatest needs and its broader commitment to reintegration and community safety.

The scientific rationale rests on a growing but still preliminary body of evidence. Phase 2 trials conducted internationally have indicated that GLP-1 receptor agonists can decrease heavy drinking among people with alcohol use disorder and reduce opioid craving among people with opioid use disorder. Prior research published in The Lancet and JAMA Psychiatry, along with earlier work on the related drug liraglutide, has suggested that these medications, originally developed to mimic gut hormones that regulate appetite and blood sugar, may also modulate reward circuitry in the brain. Researchers involved in the trial describe the effect in practical terms: rather than feeling dominated by cravings, whether for sugar, alcohol, or drugs, many patients report that GLP-1 medications help quiet that internal noise, restoring a sense of personal agency that addiction erodes.

What sets this trial apart from most addiction medication studies is the breadth of its outcome measures. Where typical trials primarily track substance use, this study will exploit Allegheny County’s nationally recognized linked administrative data infrastructure to examine whether treatment improves real-world outcomes across entire systems. Researchers will follow participants’ employment, housing stability, health care utilization and costs, mental health, self-control and impulsivity, weight, and involvement with the criminal justice system, including rearrest, reconviction, and reincarceration. The team will also calculate total fiscal and social costs, allowing the study to answer not only a clinical question but a policy one: whether any clinical benefit is large enough to justify sustained public investment.

The partnership behind the trial grew out of an unlikely collaboration between a research organization and a county government. Alex Jutca, Director of the Allegheny County Department of Human Services, described reaching out to CASPR executive director and co-founder Nicholas Reville two years ago after reading his addiction medicine blog. The two began talking regularly about GLP-1 medications, addiction, recidivism, and the challenges the county was facing, and the trial concept emerged from those conversations. The collaboration combines clinical treatment expertise, the county’s integrated data systems and social service partnerships, economic analysis, and addiction-policy expertise within a single randomized study, a structure its architects say is extremely unusual for county government.

Clinical leadership will come from UPMC Western Psychiatric Hospital’s Addiction Medicine Services, which will serve as the lead clinical site alongside other addiction treatment partners in Allegheny County. Antoine Douaihy, MD, Professor of Psychiatry and Medicine at the University of Pittsburgh School of Medicine and Senior Academic Director of Addiction Medicine Services at Western Psychiatric Hospital, said the trial examines the effectiveness and safety of GLP-1 receptor agonists and their impact on outcomes including employment, housing, health, and recidivism, noting that drug use disorders are major drivers of criminal justice involvement and intersect with systemic inequities and disparities. He expressed enthusiasm that the trial holds promise to change the landscape of addiction treatment and expand the recovery toolbox.

The research team itself is multidisciplinary by design, bringing together economists, addiction psychiatry specialists, and policy researchers from MIT, the University of Pittsburgh, the University of California San Diego, and UPMC Western Psychiatric Hospital. Named investigators include Diana Martínez Heredia of the Allegheny County Department of Human Services, Frank Schilbach and Dhruv Gaur of MIT, J. Travis Donahoe of the University of Pittsburgh, Gordon Dahl of the University of California San Diego, and Antoine Douaihy of UPMC. This composition allows the trial to be studied from clinical, economic, and behavioral angles simultaneously, an approach intended to produce evidence that can guide decisions well beyond Pittsburgh.

Indeed, scalability is a central theme of the trial’s design. Reville emphasized that because the intervention is a medication rather than a complex service program, a positive result in Pittsburgh should translate almost everywhere, making the trial easy for other cities to adopt. Jutca added that if results are positive, the county will consider the approach on an ongoing basis for individuals with substance use disorders and will work with other cities and counties across the country to disseminate findings, consistent with the broader goals of the Allegheny Recovery Partnership, which aims to build a coordinated system of care that keeps people engaged in treatment over time. Both leaders stressed that new medications become most valuable when integrated into systems that consistently support recovery.

The trial also builds on CASPR’s earlier pilot work, including a program with OpenDoors in Rhode Island that provides semaglutide to women in a post-incarceration sober housing program. Reville reported remarkable outcomes from that pilot, with women describing the disappearance of drug dreams and reporting that they felt better than they had ever felt, allowing them to rebuild careers and family relationships once cravings quieted. That program has drawn national media attention, including coverage in The New York Times and The Washington Post. Reville argued that GLP-1 medications may prove especially impactful because many patients are already familiar with the drug class and eager to take it, a level of patient enthusiasm he suggested could make a sustainable population-level impact possible and mark the most significant advancement in addiction medicine in decades.

Organizers are also attentive to the ethical dimensions of the work. Jutca said the team is working closely with community leaders and partners to ensure that trial participants are treated with respect throughout the process, noting that while addiction is widespread, its costs are unequally distributed. The county wants to demonstrate that widening inclusion in medical research is both important and possible while upholding high clinical and safety standards. CASPR, which funds and publishes research with the VA, created the first-ever pilot programs giving GLP-1 receptor agonists to patients receiving addiction treatment, and advocates for policies enabling faster medication development, is funded by individuals and foundations and accepts no direct or indirect funding from pharmaceutical companies. If the trial succeeds, its architects believe the result will be a major advance: a way to give people a better chance to recover, stay healthy, find employment, maintain stable housing, and avoid returning to the justice system.

Subject of Research: A randomized clinical trial testing whether semaglutide reduces alcohol and opioid use and justice involvement among adults with substance use disorders.

Article Title: CASPR and Allegheny County announce major new randomized clinical trial: GLP-1RA recovery and stability trial

Article References: CASPR and Allegheny County announce major new randomized clinical trial: GLP-1RA recovery and stability trial. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: semaglutide, GLP-1 receptor agonists, alcohol use disorder, opioid use disorder, randomized controlled trial, addiction medicine, recidivism, Allegheny County, CASPR, Arnold Ventures, criminal justice involvement, recovery

The starting point for the correspondence is a 2025 study by Campbell and colleagues, also published in the Journal of General Internal Medicine, which examined the impact of substance use navigators on two outcomes of obvious clinical and economic importance: initiation of treatment for substance use disorders and 30-day unplanned hospital readmission. Navigators in such models typically meet patients during or shortly after an emergency department visit, establish rapport, address practical barriers such as insurance, transportation, and appointment scheduling, and maintain follow-up contact until the patient is connected with medication for opioid use disorder, counseling, or other formal treatment. The Campbell study reported on the program’s overall effect, and the new letter by Luo and Song accepts the value of that contribution while arguing that the field now needs to ask finer-grained questions about mechanism and equity.

The first of those questions concerns dose-response. In epidemiology and clinical research, a dose-response relationship describes how an outcome changes as the level of exposure increases—in this case, how the number, duration, or intensity of navigator interactions relates to the probability that a patient initiates treatment or avoids an early readmission. Luo and Song argue that establishing such a relationship matters for more than statistical completeness. If treatment initiation rises steadily with each additional navigator contact, that pattern would support a causal interpretation of the navigator’s role and would give program designers an empirical basis for setting contact targets. If instead the relationship plateaus or is non-linear, with most benefit accruing in the first few encounters, health systems could allocate scarce navigator time more efficiently, concentrating intensive outreach on the patients who need it rather than spreading effort uniformly.

The letter situates this argument within modern causal thinking. Luo and Song cite work by Shimonovich and colleagues in the European Journal of Epidemiology that revisits the classic Bradford Hill considerations for assessing causality in epidemiology in light of contemporary developments in causal inference. That framework emphasizes that consistency, biological or mechanistic plausibility, and dose-response gradients are suggestive but not decisive on their own, and that observational findings must be interpreted with explicit attention to confounding and selection. Applied to navigator research, the implication is that a simple before-and-after comparison of treatment initiation rates cannot settle whether navigators caused the improvement, because patients who receive more navigator contact may differ systematically from those who receive less—in motivation, housing stability, insurance status, or severity of illness. Dose-response analysis, the letter suggests, is one tool among several for strengthening causal interpretation, provided it is designed with those confounders in view.

The second axis of the letter concerns socioeconomic factors. Luo and Song highlight that the effectiveness of a navigator program cannot be fully understood without attending to the social and economic circumstances of the patients it serves. Substance use disorders are strongly patterned by socioeconomic position: housing instability, unemployment, low educational attainment, lack of insurance, and limited access to transportation all raise the barriers between a patient in an emergency department and a functioning treatment linkage. A navigator intervention that appears uniformly effective in an aggregate analysis may in fact work well for some patient subgroups and poorly for others, and the letter argues that exploring these heterogeneities is essential both for scientific understanding and for equitable program design.

Support for this concern comes from a broader literature that the letter references. Birkeland and colleagues, writing in Addiction Science and Clinical Practice, examined perceived family cohesion, social support, and quality of life among patients undergoing treatment for substance use disorders, comparing them with patients treated for mental and physical disorders. Their findings underscore that social resources are not peripheral to addiction treatment but intertwined with how patients experience and sustain it. For navigators, this literature suggests that the same dose of navigator contact may translate into different outcomes depending on the family, community, and economic context surrounding each patient. A patient with stable housing and supportive family members may need relatively brief navigation to reach treatment, while a patient facing homelessness or isolation may require sustained, resource-intensive engagement that standard program protocols were not designed to provide.

The practical implications of the letter’s argument extend to how navigator programs are evaluated. Randomized trials and quasi-experimental studies of navigation have generally reported average effects across enrolled populations, and those averages have informed decisions by hospital systems and policymakers. Luo and Song’s point is that averages can conceal the dose-response structure and the socioeconomic gradient that actually determine a program’s real-world performance. An evaluation that records the number and duration of navigator contacts, stratifies outcomes by measures of socioeconomic position, and models the interaction between the two would give administrators actionable information: which patients to prioritize, how many contacts to budget for, and where supplementary social services—housing assistance, benefits enrollment, peer support—would complement navigation most effectively.

The letter also speaks to a tension familiar in implementation science: the trade-off between fidelity to a tested model and adaptation to local conditions. Navigator programs originated in cancer care and have been adapted for HIV, mental health, and substance use, with each adaptation altering the intensity and scope of the role. If dose-response analysis shows that early contacts carry most of the benefit, programs might reasonably front-load engagement in the first days after an emergency visit. If socioeconomic stratification shows that disadvantaged patients derive equal or greater benefit from extended navigation, then uniform staffing models that cap contact time may systematically underserve the patients with the greatest need. In either scenario, the letter’s framework converts a general endorsement of navigation into specific, testable design parameters.

It is worth noting the limits of what the letter itself establishes. As a correspondence item, it does not present new patient data, and its authors report no funding and declare no conflicts of interest. Its contribution is to set an agenda: future studies of substance use navigators, the authors argue, should be designed from the outset to capture contact intensity and socioeconomic context, rather than treating navigation as an undifferentiated exposure. The citation of Bradford Hill–informed causal reasoning signals that the authors want the field to move beyond association toward defensible causal claims, using designs such as stratified analyses, sensitivity analyses for unmeasured confounding, and, where feasible, randomized variation in navigator dosage.

For clinicians and health system leaders, the message is that the navigator model has earned its place in the response to substance use disorders, but that its next phase of development depends on finer measurement. The questions Luo and Song raise—how much contact is enough, for whom, and under what social conditions—are precisely the questions that determine whether navigation becomes a durable, scalable component of addiction care or a promising intervention whose benefits erode as it spreads. The letter, published as part of the Journal of General Internal Medicine’s correspondence section, is likely to shape the design of the next generation of navigator evaluations, and its emphasis on dose and equity reflects a broader shift in health services research toward understanding not just whether interventions work, but how and for whom.

Subject of Research: Dose-response relationships and socioeconomic factors in substance use navigator programs for addiction treatment linkage

Article Title: Enhancing the Impact of Substance Use Navigators: Exploring Dose-Response Relationships and Socioeconomic Factors

Article References: Luo, J., & Song, Y. (2026). Enhancing the Impact of Substance Use Navigators: Exploring Dose-Response Relationships and Socioeconomic Factors. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10813-9

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10813-9

Keywords: substance use navigators, dose-response, socioeconomic factors, emergency department, treatment initiation, hospital readmission, causal inference, Bradford Hill, health equity, addiction medicine, Journal of General Internal Medicine, implementation science

The scale of the underlying problem is enormous. Hospitalizations related to alcohol use disorder and opioid use disorder contribute to substantial illness and rising costs, collectively amounting to nearly 50 billion dollars in healthcare spending in 2022 alone. Randomized trials have long supported the use of guideline-recommended medications for these conditions, which meaningfully reduce alcohol or opioid use and improve treatment retention among patients with opioid use disorder. Observational studies have also suggested that these medications could reduce acute healthcare utilization, such as emergency department visits and hospital admissions. Against that evidence base, the treatment rates reported in national surveys are strikingly low: in 2025, only about 3 percent of Americans aged 12 years and older with alcohol use disorder reported receiving medication treatment, and only 16 percent of those with opioid use disorder reported receiving medication in the past year.

Pham and colleagues addressed the relationship between medication use and healthcare utilization using a cross-sectional analysis of US adults from the 2022–2023 National Survey on Drug Use and Health, a nationally representative survey that assesses substance use disorders based on formal diagnostic criteria. Their weighted sample represented 57.5 million adults with past-year alcohol use disorder and 2.9 million adults with past-year opioid use disorder. Within that population, only 2 percent of those with alcohol use disorder and 30 percent of those with opioid use disorder reported using medication treatment within the past year. Perhaps the most consequential single number in the analysis is this: among patients who did not receive medication treatment, the mean number of past-year outpatient visits was 3.3. In other words, many untreated patients were already seeing doctors regularly, which suggests that lack of contact with the healthcare system is not the primary barrier keeping them from evidence-based pharmacotherapy.

The utilization findings themselves were nuanced and, at first glance, counterintuitive. In stratified analyses, healthcare utilization was generally more frequent among patients who received medications for alcohol use disorder, but no consistent association emerged for those who received medications for opioid use disorder. In unadjusted analyses of patients with alcohol use disorder, past-year medication use was associated with more emergency department visits, with an incidence rate ratio of 3.10 (95 percent confidence interval 1.98–4.83), more nights hospitalized, with an incidence rate ratio of 4.10 (95 percent confidence interval 2.17–7.75), and more outpatient visits, with an incidence rate ratio of 1.76 (95 percent confidence interval 1.18–2.62). When the analysts controlled for sociodemographic factors and comorbidities, the associations with emergency department visits and nights hospitalized remained statistically significant but attenuated, at 1.91 (95 percent confidence interval 1.19–3.06) and 2.03 (95 percent confidence interval 1.09–3.79) respectively, while the association with outpatient visits was no longer significant at 1.22 (95 percent confidence interval 0.91–1.63).

For patients with opioid use disorder, the picture was different. The only significant adjusted association between medication treatment and healthcare utilization was for nights hospitalized, with an incidence rate ratio of 2.08 (95 percent confidence interval 1.22–3.55). The divergence between the two conditions is one of the study’s most intriguing puzzles, and the cross-sectional design of the dataset precludes any definitive explanation. One possibility is that patients with alcohol use disorder are offered treatment later in the course of their disease, after alcohol-associated chronic medical conditions have already developed that predispose them to higher rates of healthcare utilization. Another possibility is that the findings reflect a genuine differential effect of medication treatment across the two conditions, given that medications for opioid use disorder are generally considered more effective than those for alcohol use disorder. It also remains unknown how utilization differs depending on which specific medication is initiated and whether psychosocial treatments are delivered concurrently across different medical settings.

The demographic profile of who received treatment adds an important layer of interpretation. Adults who received medications were generally older and more socioeconomically disadvantaged than those who did not: they were less often married, less educated, more often unemployed, and had lower incomes. They also carried more medical comorbidities and had greater severity of their alcohol or opioid use disorder. To some extent, this pattern is reassuring, because it indicates that medications are reaching the population with the highest degree of social vulnerability and clinical need—the patients who stand to benefit from them the most. On the other hand, it suggests that patients are often not receiving treatment earlier in their disease course, at a point when intervention could prevent the downstream social and medical consequences of untreated addiction before they accumulate.

That late start may also help explain another persistent problem: extremely poor persistence with these medications. Prior research has documented high rates of discontinuation of medications for alcohol use disorder and limited retention in buprenorphine treatment for opioid use disorder. The greater socioeconomic disadvantage and disease severity observed among treated patients may themselves act as barriers to staying on treatment, compounding the challenge of retention. This points toward structured interventions that address social vulnerability directly—such as care navigation programs that help patients overcome logistical, financial, and coordination obstacles—as potentially necessary complements to medication prescribing if treatment is to be sustained over time.

Several methodological limitations shape how these findings should be read. Because the study is cross-sectional, the timing of medication use relative to healthcare encounters cannot be determined: it is impossible to know whether healthcare encounters preceded or followed medication initiation, so no causal relationship can be ascribed to the observation that patients receiving medications for alcohol use disorder had higher utilization. The utilization outcomes were self-reported and therefore prone to recall bias, a common trade-off in addiction health services research. National surveys like the National Survey on Drug Use and Health rely on self-reported data, but that approach yields reliable population-level prevalence estimates based on formal diagnostic criteria. Administrative data, by contrast, are compromised by selective and non-standardized screening for alcohol and opioid use disorder in many health systems, which makes case ascertainment less reliable. Future studies could explore novel data linkages or health systems with more standardized screening and documentation procedures to close this gap.

A final interpretive caution concerns the meaning of healthcare utilization itself. Even acute utilization is context-dependent and does not inherently represent a negative outcome. For a patient with an acute health condition, presenting to the emergency department may be a desirable outcome rather than a failure, particularly compared with delaying care and risking disease progression. The survey data used in this study cannot identify which healthcare encounters were preventable or directly attributable to alcohol or opioid use disorder, so higher utilization among treated patients cannot be automatically framed as harm or as treatment failure.

What the study cannot do is establish the effect of these medications on healthcare utilization, and the editorial emphasizes that any interpretation must be situated within decades of randomized trial evidence demonstrating meaningful clinical benefit. What the study does provide is a stark reminder of underutilization—even among patients who are already engaged with the healthcare system and seeing clinicians multiple times a year. The path forward, the editorial argues, lies in high-quality hybrid effectiveness-implementation trials that test strategies to increase uptake of medications for alcohol and opioid use disorder across emergency departments, inpatient wards, and outpatient settings, while simultaneously assessing clinical outcomes including subsequent healthcare utilization. With nearly 50 billion dollars in annual spending tied to alcohol- and opioid-related hospitalizations and treatment rates stuck in the single digits for alcohol use disorder, the economic and human stakes of closing that gap could hardly be higher.

Subject of Research: The association between medications for alcohol and opioid use disorder and healthcare utilization among US adults

Article Title: What is the Relationship Between Addiction Medications and Healthcare Utilization?

Article References: Bernstein, E. Y. (2026). What is the Relationship Between Addiction Medications and Healthcare Utilization?. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10885-7

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10885-7

Keywords: alcohol use disorder, opioid use disorder, medication treatment, healthcare utilization, NSDUH, emergency department visits, hospitalization, treatment retention, addiction medicine, health services research, Journal of General Internal Medicine, treatment gap

The research team, led by emergency physician Hazar Khidir of Henry Ford Hospital and including investigators at Stanford University, the University of Washington, and Yale University, assembled one of the largest cohorts ever used to study this question. Drawing on 100 percent Medicaid claims files from 2016 through 2019, they identified 234,944 acute opioid-related events among 169,721 beneficiaries aged 18 to 64. To qualify, an encounter had to involve a nonfatal emergency department visit, an acute inpatient admission, or an inpatient rehabilitation or detoxification stay tied to opioid overdose, opioid withdrawal, or an infection caused by injection drug use. These are precisely the clinical junctures that addiction medicine specialists call teachable moments, when a patient has survived an overdose or been hospitalized for a serious infection and may be uniquely receptive to starting treatment.

The technical design of the study matters for interpreting its results. The researchers tracked three primary outcomes: whether patients filled a buprenorphine prescription within 30 days of discharge, whether they filled a naloxone prescription, the nasal spray that reverses opioid overdoses, within the same window, and whether they achieved what the field calls buprenorphine retention, defined as at least 150 days of the medication on hand within 180 days of the encounter. They also examined early engagement, measured as fills within just three days. To isolate the effect of race and ethnicity from other factors, the team used hierarchical logistic regression, a statistical approach well suited to claims data because it accounts for patients being clustered within states and years. The models adjusted for age, sex, comorbid medical conditions, prior treatment history, the specific diagnosis that brought the patient in, the state of residence, and the calendar year.

The baseline numbers alone are sobering. Across all 234,944 events, only 14.08 percent of patients filled a buprenorphine prescription within 30 days, and just 3.78 percent filled naloxone. Only 4.62 percent were retained on buprenorphine at 180 days. In other words, after surviving an overdose or being hospitalized for a life-threatening infection from injection drug use, fewer than one in seven Medicaid beneficiaries started the medication most strongly associated with keeping them alive, and fewer than one in twenty stayed on it long enough to derive its full protective effect. The cohort was 68.1 percent White, 11.5 percent Black, and 11.1 percent Hispanic, with a mean age of 37.48 years and 43.36 percent female.

When the researchers compared racial and ethnic groups after statistical adjustment, the disparities emerged clearly and consistently. Compared with non-Hispanic White patients, Black patients had significantly lower adjusted odds of filling buprenorphine within 30 days across every setting studied: the odds were 21 percent lower after emergency department visits (adjusted odds ratio 0.79, 95 percent confidence interval 0.71 to 0.88), 28 percent lower after inpatient admissions (0.72, 0.63 to 0.83), and 17 percent lower after rehab or detox stays (0.83, 0.71 to 0.97). Hispanic patients fared similarly, with 20 percent lower odds after emergency visits (0.80, 0.73 to 0.88) and 17 percent lower odds after inpatient admissions (0.83, 0.75 to 0.93). These are not marginal differences confined to one corner of the health system; they span the entire acute care continuum.

The retention findings were even more alarming. Among patients who did manage to start buprenorphine, Black patients had 36 percent lower adjusted odds of being retained at 180 days after an emergency department encounter (0.64, 0.55 to 0.74), 49 percent lower odds after an inpatient stay (0.51, 0.43 to 0.60), and 37 percent lower odds after rehab or detox (0.63, 0.48 to 0.82). Hispanic patients showed 30 percent lower odds after emergency visits (0.70, 0.62 to 0.79) and 34 percent lower odds after inpatient admissions (0.66, 0.56 to 0.78). An odds ratio of 0.51 means that, after accounting for every measured confounder, a Black patient hospitalized for an opioid-related crisis had roughly half the chance of a comparable White patient of still being on medication six months later. Retention is the single most important predictor of buprenorphine’s mortality benefit; studies have shown that interruptions in medication dramatically raise overdose risk.

The study’s focus on Medicaid is deliberate and consequential. Medicaid is the dominant payer for people with opioid use disorder in the United States, covering a population that bears a disproportionate share of the overdose burden. Because the program insures patients across state lines and across every type of acute care setting, it offers a rare, near-complete window into how the treatment system actually performs. Prior work had already documented a racial divide in buprenorphine access: a 2023 analysis in the New England Journal of Medicine found racial inequality in the receipt of medications for opioid use disorder, and studies of emergency departments across five health systems showed that Black patients were less likely to be started on buprenorphine during their visits. The new study extends that evidence to the post-discharge period and to inpatient and detoxification settings, using a multi-state design that rules out the possibility that the gaps are an artifact of any single state’s policy or any single hospital’s practice.

Why do these disparities persist even after adjusting for diagnosis, comorbidity, and prior treatment? The authors and the broader literature point to a layered set of mechanisms. On the provider side, clinicians may offer buprenorphine less often to patients of color, a pattern documented in emergency department studies and consistent with a bifurcated treatment system in which White patients are more often steered toward office-based medication while Black and Hispanic patients are channeled toward abstinence-oriented or criminal-legal pathways. On the structural side, counties with high levels of racial and ethnic segregation have less treatment capacity for opioid use disorder, meaning that even a motivated patient may leave a hospital without a nearby prescriber. Medicaid itself adds friction: prior authorization requirements and managed care formulary restrictions vary by state and can delay or block fills, and pharmacy deserts are more common in predominantly Black and Latino neighborhoods. Naloxone distribution, meanwhile, has historically under-reached communities of color even as fentanyl has made overdose risk universal.

The consequences of these gaps are measured in lives. Buprenorphine reduces mortality during treatment, and the period immediately after an overdose or hospital discharge is one of extreme vulnerability, with overdose risk elevated for weeks. Every failure to initiate or sustain medication during a transitional window compounds that risk. The study’s authors argue that improved transitional care, warm handoffs from emergency departments and hospitals to community-based treatment, overdose education, take-home naloxone, and follow-up appointments, combined with targeted Medicaid reforms such as streamlined coverage of medications and enhanced payment for transitional care management, could close the gap. The elimination of the federal buprenorphine waiver requirement, often called the MAT Act, has removed one prescriber-level barrier, but the new findings suggest that prescriber-level change alone will not be sufficient.

What makes this study resonate beyond the specialty literature is its scale and its consistency. Nearly a quarter of a million acute opioid-related events, spanning 19 states and four years, all point in the same direction: at the moments when the health system has the greatest leverage over the trajectory of opioid use disorder, Black and Hispanic patients are systematically less likely to receive and keep the treatment that best prevents death. The opioid crisis has often been described as having shifted demographically, with rising overdose rates among Black Americans in recent years, yet the treatment infrastructure has not kept pace with that shift. As policymakers weigh Medicaid reforms and health systems build out addiction consult services and emergency department buprenorphine programs, the study offers a clear benchmark: equitable access must be measured not just in who walks through the door, but in who leaves with a prescription filled, and who is still taking their medication six months later.

Subject of Research: Racial and ethnic disparities in buprenorphine and naloxone receipt and retention among Medicaid beneficiaries after acute opioid-related care

Article Title: Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations

Article References: Khidir, H., Nedelec, L., Sebok-Syer, S. S., Sabbatini, A. K., Shin, I., Melnick, E. R., & Lin, M. P. (2026). Racial and Ethnic Disparities in Buprenorphine and Naloxone among Medicaid Beneficiaries after Emergency Department Visits and Hospitalizations. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10838-0

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10838-0

Keywords: opioid use disorder, buprenorphine, naloxone, Medicaid, health disparities, emergency department, hospitalization, treatment retention, overdose, addiction medicine, health equity, transitional care

The three-day rule is a provision of federal regulation that permits practitioners who are not affiliated with an OTP to administer methadone to a patient for the purpose of relieving acute withdrawal symptoms while arranging referral to a licensed program. The allowance is capped at three days, and it cannot be renewed within the same month. In practice, it has historically been used sparingly, because clinicians have worried about safety and because the short window seems ill-suited to overcoming the administrative delays that often accompany OTP enrollment. The new research, published in the journal Addiction Science & Clinical Practice, offers a detailed real-world test of the approach as implemented at the San Francisco General Hospital Bridge Clinic, a low-threshold service designed to meet patients where they are.

The study team, led by Sarah Rosenwohl-Mack of UCSF’s Department of Family and Community Medicine, conducted a retrospective case series covering every patient who initiated methadone under the three-day rule at the Bridge Clinic between June 2024 and July 2025. The setting is notable for an unusual piece of geography: the hospital also houses an opioid treatment program in the same building. When that program could not complete an intake, for example because a patient arrived outside scheduled intake hours or the program was at capacity, staff could refer the person down to the Bridge Clinic, where a dose of methadone could be started immediately under the three-day provision. This bidirectional referral pathway became the study’s central variable.

The researchers tracked two primary outcomes. The first was linkage to an OTP within seven days of receiving the initial Bridge Clinic dose, a window that extends beyond the three-day medication allowance and therefore captures whether the bridge actually carried patients to permanent care. The second was retention in OTP treatment at 30 days, a marker of early stability that addiction medicine researchers view as a meaningful predictor of longer-term benefit. Because methadone carries its own risks, particularly when combined with other sedatives, the team also built in a safety monitoring framework that reviewed urine drug screens, emergency department visits, hospitalizations within seven days, and Medical Examiner overdose reports.

The results are striking for a population that conventional systems routinely lose. Among 166 unique patients who received at least one dose of three-day methadone at the Bridge Clinic, 63 percent, or 104 individuals, successfully linked to an opioid treatment program within seven days. Of those who linked, 62 percent, or 64 patients, were still retained in treatment at the 30-day mark. In a field where attrition between first contact and enrollment has long been considered one of the most stubborn leaks in the continuum of care, the finding suggests that a short bridge of medication can hold a substantial fraction of patients long enough for the formal system to catch up with them.

The most consequential finding, however, concerned the direction of the referral. Using multivariable logistic regression to adjust for other factors, the researchers found that patients who arrived at the Bridge Clinic by referral from the co-located OTP had 3.1-fold higher odds of remaining in treatment at 30 days compared with patients who came through other routes. The interpretation is not that the referral itself dispensed a pharmacological benefit, but that the pathway reflects a coordinated system in which the OTP and the Bridge Clinic function as two doors into the same building of care. A patient handed off from the OTP arrives with an established clinical relationship, a documented treatment plan, and a clear route back, whereas a patient walking in cold must navigate enrollment largely on their own after the three-day window closes.

On the safety side, the record was clean in ways that will reassure clinicians who have hesitated to use the three-day rule. The study identified no methadone-related emergency department visits, no hospitalizations, and no deaths within 30 days of receiving methadone at the Bridge Clinic. The urine drug screen review, designed to flag unexpected results such as methadone positivity in patients not prescribed it or the absence of non-prescribed opioids suggesting diversion, surfaced only one notable case: a single patient who, on closer chart review, turned out to have already been enrolled in methadone treatment elsewhere before receiving a dose at the Bridge Clinic. That finding points to a practical quality-control challenge, ensuring that bridge dosing does not duplicate existing treatment, but it does not undermine the overall safety signal.

The technical logic of the intervention deserves attention. Methadone is a long-acting full mu-opioid receptor agonist with a half-life that supports once-daily dosing, which is precisely why it smooths the cycle of withdrawal and craving that drives much of the daily chaos in untreated opioid use disorder. When a patient presents in withdrawal, the clinical task is to provide enough of the medication to relieve symptoms without accumulating toxicity, which is why Bridge Clinic protocols begin with conservative doses and titrate carefully. The three-day rule fits neatly into this pharmacology: three days of supervised dosing is enough to stabilize a patient physiologically and to interrupt the withdrawal-driven urgency that otherwise pushes people back to fentanyl and other illicit opioids, while the referral machinery works in parallel to secure a permanent slot at an OTP.

The San Francisco team acknowledges intellectual debts in the paper, crediting the Faster Paths Emergency Opioid Withdrawal Protocol at Boston Medical Center, whose published approach informed the local protocol. That lineage matters because it illustrates how low-threshold models are spreading through a kind of open-source clinical adaptation, with programs borrowing and refining each other’s protocols rather than waiting for multi-year trials. The study itself was deemed exempt by the UCSF Institutional Review Board and used retrospectively collected anonymized data, a design that trades the rigor of randomization for the realism of observing how an intervention performs inside the ordinary friction of a public hospital.

The implications reach well beyond one clinic. Opioid treatment programs remain the only legal channel for methadone maintenance in the United States, and their geographic maldistribution means that many counties have no OTP at all. The three-day rule cannot substitute for structural reform, but the study demonstrates that when a low-threshold bridge service and a licensed OTP are deliberately networked, the rule becomes a functional handoff mechanism rather than a rarely used legal footnote. The 3.1-fold retention advantage associated with OTP referral suggests that the return on investment lies in building those connections, ensuring that every bridge dose is paired with a warm pathway back into licensed care. For a lethal epidemic that has proven resistant to conventional outreach, the message is deceptively simple: meet people in withdrawal with medication the same day, and engineer the system so that the door they entered stays open behind them.

Subject of Research: Three-day methadone bridging at a low-threshold clinic to improve linkage and retention in opioid treatment programs

Article Title: Implementing three-day methadone in a low-threshold Bridge Clinic: impact of OTP referral pathways on treatment retention

Article References: Rosenwohl-Mack, S., Suen, L. W., Hart, R., Steiger, S., Hom, J. K., & Snyder, H. (2026). Implementing three-day methadone in a low-threshold Bridge Clinic: impact of OTP referral pathways on treatment retention. Addiction Science & Clinical Practice. https://doi.org/10.1186/s13722-026-00725-8

Image Credits: AI Generated

DOI: 10.1186/s13722-026-00725-8

Keywords: methadone, opioid use disorder, opioid treatment program, Bridge Clinic, three-day rule, treatment retention, harm reduction, San Francisco General Hospital, low-threshold care, withdrawal management, addiction medicine, medication for opioid use disorder

The research, led by Karen L. Roper of the University of Kentucky College of Medicine’s Department of Family and Community Medicine, addresses a well-documented gap in the treatment landscape. Medications for opioid use disorder, commonly abbreviated as MOUD, are demonstrably effective at reducing illicit opioid use, overdose mortality, and relapse, yet the majority of people with opioid use disorder in the United States receive no pharmacological treatment at all. Buprenorphine, a partial opioid agonist that suppresses cravings and withdrawal without producing the full euphoric effect of full agonists, can be prescribed in office-based settings, making primary care an ideal delivery channel. Despite this, many primary care practitioners, or PCPs, cite a thicket of barriers: worry about staff and patient reactions, limited appointment time, reimbursement uncertainty, and a lack of confidence in managing a condition long stigmatized as outside the generalist’s lane.

What distinguishes this intervention is its deliberate grounding in the science of behavior change. Rather than producing generic continuing education content, the team scripted videos specifically tailored to the primary care environment, and especially to the realities of rural practice. The central video was delivered by a rural-setting PCP who described her extensive firsthand experience treating patients with buprenorphine, directly confronting the negative perceptions and practical barriers that clinicians most often raise. Supplementary videos were designed around two distinct motivational pathways: one emphasizing external motivation, such as clinic-level and societal benefits of expanding MOUD access, and the other emphasizing internal motivation, including the personal and professional rewards of treating addiction.

Methodologically, the study took the form of cross-sectional surveys administered through a continuing education platform alongside the videos. Participation was open to family and internal medicine professionals in Kentucky, including physicians, doctors of osteopathy, advanced practice registered nurses, and physician assistants. The survey instrument captured demographic information and career satisfaction, and used a Post/Retrospective-Pre format to assess change in the perceived importance of 19 distinct barriers to MOUD practice, along with confidence in four relevant practice areas. The retrospective-pre design asks respondents to rate their views before the intervention in hindsight after completing it, a technique that can capture shifts that participants might not have recognized in real time. The primary outcome was the learner’s stated intention to explore MOUD, while secondary measures rated the educational content for gains in clinical knowledge and skills and for usefulness of information.

The results, though drawn from a modest sample of 37 professional learners, were statistically meaningful. After viewing the videos, participants rated several prominent barriers as significantly less important, including concern about negative attitudes and perceptions across the practice, spanning staff, other practitioners, and patients; limited appointment time; and reimbursement of clinical visits. Fisher’s non-parametric tests yielded p-values at or below 0.05 for these reductions, suggesting the changes were unlikely to be due to chance alone. Perhaps most strikingly, the intervention appeared to touch something deeper than logistics: participants reported a strengthened sense that offering MOUD fits with one’s calling as a physician, an internal-motivation construct that the supplementary videos were explicitly designed to activate.

Behavioral intentions shifted as well. Viewers reported an increased likelihood to screen patients for opioid use disorder, a critical first step in the treatment cascade, since undiagnosed opioid use disorder cannot be treated. The study also uncovered an intriguing correlate: practitioners who scored higher on career satisfaction were more likely to consider board certification as an Addiction Medicine Specialist. This finding hints that clinician well-being and workforce development in addiction medicine may be intertwined, and that educational interventions could be tailored to leverage the professional fulfillment that many physicians derive from treating a condition they once avoided.

Open-ended feedback collected in the survey added qualitative texture to the quantitative findings, probing viewers’ reactions to specific aspects of the video content and its general impact. While the published abstract does not detail individual responses, the inclusion of these questions reflects a deliberate effort to understand not just whether the videos worked, but why, information that will be essential for scaling the approach beyond a single state. The educational content itself was rated positively for gains in clinical knowledge and skills and for the usefulness of the information presented, suggesting the format succeeded as continuing education even before its attitudinal effects are considered.

The significance of this work lies less in any single statistic than in its proof of concept. Expanding buprenorphine access has been a federal policy priority for years, with regulatory reforms eliminating the former X-waiver requirement and encouraging mainstreaming of addiction treatment into general medicine. Yet policy change alone has not moved the needle far enough, because the remaining barriers are psychological and cultural as much as regulatory. By demonstrating that brief, peer-delivered, behaviorally targeted video education can reduce the perceived salience of those barriers, the Kentucky team offers a low-cost, scalable template. A rural physician speaking to her peers in their own professional language may accomplish what guidelines and mandates have not.

The study’s limitations invite caution. With 37 participants drawn from a single state through a continuing education platform, the sample is small and self-selected; clinicians motivated enough to watch addiction-focused education may already be predisposed toward MOUD. The cross-sectional design cannot establish long-term durability of attitude change, and stated intention to explore MOUD does not guarantee that viewers will ultimately obtain the training and workflow supports needed to prescribe. Still, the authors conclude that education conceived for and specifically responsive to the primary care environment, and especially to the challenges of rural practice, can help overcome perceived barriers and promote consideration of MOUD service in primary care settings. In a crisis that claims tens of thousands of American lives annually, converting even a fraction of the nation’s primary care clinicians into buprenorphine prescribers could translate directly into saved lives, and this study suggests the conversion may begin with nothing more complicated than a colleague telling her story on camera.

Subject of Research: Impact of targeted educational videos on primary care practitioners' attitudes and intentions toward providing buprenorphine for opioid use disorder

Article Title: Changing minds on MOUD: impact of messages to motivate expanded access to buprenorphine in primary care settings

Article References: Roper, K. L., Zook, M., Heier, K., McQuerry, K., Marks, S., & Knudsen, H. K. (2026). Changing minds on MOUD: impact of messages to motivate expanded access to buprenorphine in primary care settings. Addiction Science & Clinical Practice. https://doi.org/10.1186/s13722-026-00719-6

Image Credits: AI Generated

DOI: 10.1186/s13722-026-00719-6

Keywords: buprenorphine, opioid use disorder, primary care, MOUD, rural health, continuing education, behavior change, addiction medicine, clinician attitudes, Kentucky, cross-sectional survey, career satisfaction